RUNX1i cotreatment partially rescues the erythroid-to-myeloid conversion by LSD1i. (A) CD71/CD235a staining of human CD34⁺ cells showing erythroid differentiation at day 11, after 4 days of treatment with CCG50 alone (300 nM or 1 μM), RUNX1i Ro5-3335 alone (10 μM-120 nM) or both. (B) mRNA abundance of γ-globin and β-globin at day 11 after inhibitor treatments. γ-Globin transcripts in DMSO were arbitrarily set at 1. Data are mean ± standard deviation. *P < .05, **P < .01, unpaired Student t test. h, human; n.s., not significant.